Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer with marginal life expectancy. Based on the assumption that GBM cells gain functions not necessarily involved in the cancerous process, patient-derived glioblastoma cells (GCs) were screened to identify cellular processes amenable for development of targeted treatments. The quinine-derivative NSC13316 reliably and selectively compromised viability. Synthetic chemical expansion reveals delicate structure-activity relationship and analogs with increased potency, termed Vacquinols. Vacquinols stimulate death by membrane ruffling, cell rounding, massive macropinocytic vacuole accumulation, ATP depletion, and cytoplasmic membrane rupture of GCs. The MAP kinase MKK4, identified by a shRNA screen, represents a critical signaling node. Vacquinol-1 displays excellent in vivo pharmacokinetics and brain exposure, attenuates disease progression, and prolongs survival in a GBM animal model. These results identify a vulnerability to massive vacuolization that can be targeted by small molecules and point to the possible exploitation of this process in the design of anticancer therapies.
INTRODUCTION
Tumor development involves mutations that can be gain-of-function mutations in proto-oncogenes or loss-of-function mutations in tumor suppressor genes that lead to fundamental changes in the biology of the cell, resulting in cancer. Genomic studies of hundreds of glioblastoma multiforme (GBM) samples have led to a comprehensive insight into the genomic landscape of GBM, revealing both gain-and loss-of-function in core signaling pathways commonly activated, including the receptor tyrosine kinase (RTK/RAS) oncogenic pathway with alterations in EGFR/ PDGFRA/PI3K/PTEN/NF1/RAS, the p53 pathway with changes in TP53/MDM2/MDM4/p14ARF, and finally, the cell-cycle regulatory pathway with alterations in RB1/CDK4/p16INK4A/ CDKN2B, with most GBM tumors having genetic alteration in all three pathways (Chen et al., 2012b; Furnari et al., 2007; Parsons et al., 2008; Brennan et al., 2009 Brennan et al., , 2013 Verhaak et al., 2010; Cancer Genome Atlas Research Network, 2008) . The consequence is a fueling of cell proliferation and enhanced survival and invasion properties, while preventing tumor cells from apoptosis and activation of cell-cycle checkpoints. Consistently, malignant gliomas are among the most devastating human cancers . GBM is essentially incurable, even when aggressive therapies based on surgical tumor resection and concomitant chemotherapy and radiotherapy are implemented (Stupp et al., 2005) , and only 3%-5% of patients survive longer than 3 years due to disease recurrence (Dolecek et al., 2012) .
The small population of GBM cells with stem/progenitor cell characteristics (Hemmati et al., 2003; Singh et al., 2003 Singh et al., , 2004 seed growth of new tumors (Gallo et al., 2013; Pollard et al., 2009; Singh et al., 2003 Singh et al., , 2004 and drive malignancy, metastasis, and tumor recurrence, promoting resistance against radiationbased therapy (Bao et al., 2006) and chemotherapy (Bleau and Holland, 2009; Chen et al., 2012b) . These tumor-initiating cells are believed to be relatively quiescent (Alcantara Llaguno et al., 2009; Barami et al., 2009) , which could contribute to disease recurrence following current therapeutic strategies targeting intracellular processes associated with cell division.
Unlike several other forms of cancer in which identification of participating gene products have resulted in series of drugs neutralizing the function gained by the genetic alterations, the complexity and diversity of glioblastoma genetics have prevented a simple strategy for therapeutic targeting. New approaches focused on neutralizing abnormalities underlying tumor development have only had limited success so far (Dent et al., 2008; Polivka et al., 2012) . We reasoned that gene products causing glioma are part of signaling pathways that are involved in diverse cellular functions. Therefore, gain-and loss-of-function mutations would be predicted to lead to acquired functions also in cellular properties not necessarily involved in cell transformation and proliferation. Hence, there should be unique cellular properties of glioma that are low or absent in other cell types. If identified, such features can be exploited for development of conceptually new strategies of therapy. In an unbiased phenotypic screen using a diversity set of small molecules on glioblastoma cells (GCs), a biological process resulting in a robust loss of viability and increased cytotoxicity was discovered. GCs are vulnerable to an MKK4-dependent signaling inducing catastrophic vacuolization and cell death.
RESULTS

Induction of Rapid and Specific Cell Death of Glioma Cells by a Small Molecule
In order to identify pathways vulnerable for targeted treatment of GCs, a phenotypic screen was performed to identify compounds active on GCs without affecting embryonic stem cells or human fibroblasts. GC cultures were independently generated from two cases of GBM, according to Pollard et al. (2009) which allows for adherent growth of cells with tumor-initiating and stem-like properties. These cell lines, designated U3013MG and U3047MG, were screened, rescreened, and confirmed using 1,364 compounds of the NIH diversity set II for phenotypic changes observed following phalloidin staining ( Figure 1A and Figure S1A available online). 234 compounds showed effects after 2 days with principal phenotypes observed designated as tiny (T, dead or reduced cell size) or loose or fuse (LOF, senescence-like morphology), respectively ( Figures 1B-1D ). Filter screens against mouse embryonic stem cells (mESCs) and human fibroblasts reduced the initial 234 compounds to 63 with effects selective for GCs ( Figures 1A and S1B ). The compounds were confirmed active on U3013MG and U3047MG GCs, as well as on seven other patient-derived GC cultures that were established (U3024MG, U3017MG, U3031MG, U3037MG, U3086MG, U3054MG, and U3065MG; Figures 1A and S1E). The 63 compounds (Table S1) were examined in a recovery assay (Figures S1C and S1D) by quantification of cytotoxicity, apoptosis, and cell viability ( Figure S2A ) in U3013MG GCs and human fibroblast cells, as well as cell-cycle analysis by flow cytometry ( Figure S2B ). In the recovery assay, 2 days with compound were followed 2 more days without compound. Only 12 compounds had an irreversible effect at the same concentration that caused the acute effects ( Figures S1C and S1D ). Quantification of cell viability (ATP) and cytotoxicity (CytoTox-Glo) of the 63 compounds identified partly the same hit compounds (i.e., E5, E10, and A7) as most efficacious with limited effects on fibroblasts ( Figure S2A ). Based on these analyses and in silico absorption, distribution, metabolism, and excretion (ADME) prediction ( Figures S3A-S3J ), a refined list of 17 hits (Table S2) was pursued using several parameters, including cell-type-selective in vitro and in vivo efficacy, Ca 2+ imaging, and toxicity tests. A hanging drop-based mixed culture procedure was developed for assaying selectivity ( Figures S4A and S4B ). U3013MG GCs and fibroblasts labeled with cell tracker red or green fluorescent dye, respectively, in cocultures confirmed selectivity (Figure S4B ). Only one compound (D1) induced Ca 2+ flux in GCs (Figures S4C-S4E ). To measure toxicity, increasing concentrations of the 17 hits administered to the water of 10 days postfertilization (dpf) zebrafish embryos revealed that, whereas B6, B11, E5, E9, C2, C7, and D12 did not affect zebrafish development, embryos died, decayed, or displayed yolk edema in the presence of the remaining hits ( Figure S5A ). Cardiovascular toxicity of ex vivo adult zebrafish hearts (Kitambi et al., 2012) was observed for four hits (A2, A6, C9, and E9) whereas small or no effects were found on the remaining compounds ( Figure S5B ). In vivo efficacy was examined in a zebrafish GBM model that was developed where 3,000 U3013MG GCs labeled with cell tracker red were injected intracranially into the ventricle of 48-52 hpf larvae. The 17 hits administered to the egg water at the lowest effective in vitro cytotoxic concentration and monitoring tumor development 10 days later revealed that B7, C2, and E5 markedly reduced tumor size, with E5 being most potent (Figure S5C) . Based on these analyses, further studies were focused on compound E5, which we name Vacquinol-1 due to its quinoline-alcohol scaffold ( Figure 1E ). Vacquinol-1 displayed high cytotoxicity (15 mM, 12 hr; Figure 1F ), led to a complete loss of viability as measured by ATP depletion ( Figure 1G ), and selectively targeted GCs in mixed cocultures with human fibroblasts ( Figures 1H and 1I ). Vacquinol-1 did not affect mESCs, human fibroblasts, or osteosarcoma cells ( Figures 1J-1O ) but rapidly reduced the proportion of GCs in S and G2/M cell-cycle phases (7.5 mM, 12 hr; Figure 1P ). Cell density had only minor effects on viability in dose response assays ( Figure 1Q ). The median inhibition concentration of 50% (IC 50 ) was 2.36 mM (3,000 cells/cm 2 , 24 hr, Figure 1R ) as compared to 139 mM by temozolomide ( Figure 1S , 48 hr), a commonly used drug for treating glioma. The IC 50 of Vacquinol-1 remained largely similar at 2, 3, and 4 days of incubation ( Figures 1T-1V ). Mouse glia and neuron cultures showed an IC 50 of 15 and 29 mM, respectively (24 hr, Figures 1W and 1X) , and fibroblasts showed an IC 50 of 18.7 mM and 23 mM (24 and 96 hr, respectively; Figures 1Y and 1Z ). The IC 50 of fibroblasts was not affected by changing to GC culture medium during Vacquinol-1 treatment ( Figures S1F and S1G) . Furthermore, Vacquinol-1 was ineffective on bladder, prostate, breast, and neuroblastoma cancer cell lines ( Figure S1H ).
Induction of a Catastrophic Unconventional Cell Death
Pathway by Vacquinol-1 Apoptosis is associated with a rapid loss of ATP. Vacquinol-1 administration (7.5 mM, 7 hr) led to a marked and significant increase of dead cells analyzed by flow cytometry, similar to staurosporin (1 mM, 7 hr; Figures 2A-2F ). The apoptosis inhibitor Q-VAD only modestly rescued cells from death at 3 and 7 hr ( Figure 2F ). Active cleaved Caspase-3 was not increased by Vacquinol-1 as compared to vehicle-treated cultures, whereas doxorubicin (10 mM) markedly increased positive cells (L-N) TMRE and ER tracker staining of GCs after 7 hr exposure to DMSO or 7.5 mM Vacquinol-1 followed by quantification of TMRE intensity (N). Scale bars, 50 mm (G-J, L, and M). Abbreviations: a.u., arbitrary units; ns, not significant; RLUs, relative luminescence; Sta, Staurosporin; Vacq, Vacquinol-1. Mean ± SD; t test, **p < 0.01 to DMSO.
( Figures 2G-2J ). Caspase-3 and Caspase-7 enzymatic activity was measured between 5 and 600 min after addition of Vacquinol-1 at increasing concentrations (5-30 mM). Unlike staurosporin, Vacquinol-1 had no effect on caspase activity at any concentration or time point ( Figure 2K ). The accumulation of tetramethylrhodamine ethyl ester (TMRE) in mitochondria and the endoplasmic reticulum is driven by their membrane potential. TMRE incorporation in mitochondria was largely unaffected by Vacquinol-1 (7.5 mM, 7 hr; Figures 2L-2N ). In ratiometric calcium imaging with ATP as positive control, cytosolic calcium flux was not affected by Vacquinol-1 ( Figures 3A, 3B , 3A 0 , and 3B 0 ). These results show that Vacquinol-1-induced GC death occurs by a nonapoptotic mechanism and does not involve a disruption of active mitochondria.
Autophagy-associated cell death is the most widely studied form of nonapoptotic cell death (Gozuacik and Kimchi, 2007) . LC3-II is conjugated to phosphatidylethanolamine on autophagosomic membranes. Vacquinol-1 did not increase LC3-II immunoreactivity ( Figures 3C and 3D ). Scanning electron microscopy on Vacquinol-1-treated GCs revealed a rapid rounding of cells and appearance of membrane invaginations curved into craterlike cups on the cell surface membrane ( Figure 3F , arrowheads), indicating an endocytic-like activity. Consistently, live-cell imaging at high magnification revealed the formation of spherical protrusions, blebs, appearing within seconds of exposing the cells to Vacquinol-1 (Movie S1). With standard phase contrast optics, live imaging revealed within minutes of Vacquinol-1 exposure (15 mM) cell rounding and the formation of massive membrane ruffles and eventual death of cells by a rupture of the cytoplasmic membrane, preceded by a marked contraction of the cytoplasmic membrane followed by uncontrolled expansion resulting in its rupture ( Figure 3G and Movies S2 and S3). Live imaging with Nomarski optics showed a rapid formation of intracellular vacuoles and membrane invaginations within 10 min of Vacquinol-1 (3.5 mM) with a dose-dependent increase of vacuole formation. Vacuole size and numbers increased with time ( Figure 3H and Movie S3) and led to displacement of the cytoplasm with large vacuoles and eventually cell rupture. These results confirm an induction of endocytic-like activity by Vacquinol-1.
Using orthogonal (z stack projection) overlap of several brightfield focal planes in a 3D image stack taken from a single-well image field, large vacuoles of varying sizes were clearly observed as lucent, a characteristic of vacuoles resulting from macropinocytosis ( Figure 4A ). Another unique feature of macropinocytosis is a large nonselective internalization of fluid trapped beneath the projections of plasma membrane during membrane ruffling (Mercer and Helenius, 2012; Swanson, 2008) . Hence, rapid incorporation of extracellular-phase fluid tracers is a hallmark of macropinosomes. The tracer lucifer yellow (LY) in the medium was taken up in most or all cells within 20 min (Figures 4B-4E; 7.5 mM Vacquinol-1) with an appearance within vacuoles . Internalization of LY was observed occasionally in nonstimulated GCs but at a very low rate compared to Vacquinol-1. Clathrin-independent endocytosis of the macropinocytosis type is sensitive to the specific inhibitor of the vacuolar-type H + -ATPase, Bafilomycin A1 (Baf-A) (Kaul et al., 2007; Overmeyer et al., 2011) . A short-term (1 hr) incubation of GCs with 100 nM Baf-A had no effect by itself on uptake of LY but completely abrogated Vacquinol-1-induced LY uptake ( Figure 4I ). Macropinocytosis is also sensitive to perturbation of the activity of Dynamin by dynasore (Gold et al., 2010) and actin by Cytochalasin D (Grimmer et al., 2002) , which both completely prevented LY uptake, whereas inhibition of the clathrin-dependent pathway with chlorpromazine was ineffective ( Figure 4I ). Transmission electron microscopy (TEM) confirmed induction of a massive vacuolization in cells (7.5 mM, 6 hr; Figures 4J-4O ). Clathrincoated endosomes are regular in size and are bounded by double membrane. The numerous vacuoles observed in GCs were large and of varying size, mostly empty and bounded by a single membrane ( Figures 4N and 4O ), features that are consistent with macropinosomes (Overmeyer et al., 2008) . The lucent vacuoles were distinct from lysosomes, autolysosomes, and late endosomes, which typically contain electron-dense organelle remnants or degraded cytoplasmic components. Swollen endoplasmic reticulum and mitochondria and distorted bilayer structures of nuclear membrane was occasionally observed (Figures 4N, 4O, and S6) . In cells on the verge of lysis, the vacuoles had typically expanded to a point where much of the cytoplasmic membrane was disrupted ( Figure 4M ). Macropinosomes vary in size from 0.5-5.0 mm, which is consistent with the range of Vacquinol-1-induced vacuoles quantified by TEM (7.5 mM, 6 hr; Figure 4P ). Macropinocytic vacuoles recruit the late endosomal and lysosomal marker LAMP1. Consistently, a marked increase of LAMP1 immunofluorescence was observed that occasionally also was associated with membrane protrusions (7.5 mM, 6 hr; Figures 4Q-4T). These results provide evidence for initiation of massive macropinocytosis by Vacquinol-1, leading to catastrophic vacuolization and resulting in a necrotic-like cell death.
Requirement of MKK4 Activation for Vacquinol-1-Induced Macropinocytosis
An unbiased short hairpin RNA (shRNA) screen was used to identify pathways for Vacquinol-1-induced vacuolization. The approach was based on the idea that depleting a key factor in the pathway should render GCs refractive to Vacquinol-1-induced death. A DECIPHER lentiviral shRNA library consisting of 27,500 shRNAs covering 5,043 target genes (Human Module 1) were used to transduce U3013MG GCs. Surviving cells after 24 hr of Vacquinol-1 (14 mM; Figure 5A ) displayed markedly different cell appearance ( Figures 5B and 5C ). The resulting Vacquinol-1-resistant GCs displayed an IC 50 of 14.3 ± 1.16 mM on GC viability ( Figure 5D ), similar to fibroblasts (IC 50 of 18.7 ± 0.06 mM). Sequencing of DNA prepared from the resistant GCs revealed an enrichment of MAP2K4 shRNA viruses ( Figure S7A ). Fluorescence staining and western blot analyses of GCs for activating phosphorylation of MKK4 encoded by MAP2K4 revealed a rapid and pronounced activation by Vacquinol-1 (7.5 mM) from 5 min to 26 hr of stimulation . No effect on histone H3K27 methylation was observed ( Figure 5K ). Abrogation of MKK4 activity by two independent shRNAs led to marked increase of the IC 50 viability of Vacquinol-1-treated GCs (94% knockdown of protein level, n = 3; Figures 5L, S7B, and S7C). Phosphorylated MKK4 rapidly organized as punctate cytoplasmic staining in Vacquinol-1-treated cells (7.5 mM, 12 hr; Figures 5M and 5N ). These results identify activation of MKK4 as a (C and D) LC3-II immunoreactivity (Vacquinol-1, 7.5 mM).
(E and F) SEM analyses of GCs (7.5 mM Vacquinol-1 for 7 hr, red arrowheads point at membrane indentations).
(legend continued on next page) critical node in the signaling pathway executing Vacquinol-1-induced death of GCs. MKK4 was confirmed required for the process of Vacquinol-1-induced macropinocytosis. Thus, following knockdown of MAP2K4, GCs became refractory to Vacquinol-1-induced vacuolization and LY incorporation ( Figures 5O-5U ), similar to osteosarcoma cells ( Figures 5S and 5T) , showing that resistance to death is associated with a defective formation of macropinocytic vacuoles induced by Vacquinol-1. Thus, the distinctive feature of vulnerability to macropinocytosis and death in GCs requires MKK4 activity.
Efficacy of Vacquinols Is Governed by Selective Chemical Features
Acquisition of structural analogs from NCI/DTP (http://dtp.cancer. gov), along with chemical synthesis (Extended Experimental Procedures; Data S1), was used for identification of potent derivatives, as well as insight into the SAR of Vacquinol-1 (Figure 6 ). Key chemical features critical for efficacy were identified by measurements of IC 50 in viability assay. Ab-hydroxyamino moiety in the 4 position of the quinoline core was invariably crucial. In accordance, all analogs containing either the ketone or carbamide in this position were inactive ( Figure 6 , compounds 2-3), as was the analog without this moiety ( Figure 6 , compound 5). Replacing piperidine with pyrrolidine ( Figure 6 , compound 6) marginally attenuated activity, whereas pyridine ( Figure 6 , compound 7) as an isostere of piperidine resulted in a complete loss of potency. Piperidine N-methylation ( Figure 6 , compound 8) gave a dramatic drop in effect, whereas methylation of the vicinal alcohol was tolerated ( Figure 6, compound 4) . Surprisingly, three of the four possible stereoisomers of Vacquinol-1 were roughly equipotent, with one isomer slightly less active (data not shown).
The quinoline core and 2-(4-chlorophenyl) moiety were more tolerant of variation, as the corresponding benzoquinoline ( Figure 6 , compound 15) resulted in the hitherto most potent compound identified in the Vacquinol series (IC 50 = 0.39 mM). Additional positions of the core scaffold were amenable to functionalization with slight or no effect on activity (e.g., compound 13 and 14).
The 2-phenylquinoline core structure also appeared to be crucial for activity, as the analogous 4-pyridinyl compounds with (Figure 6, compound 20) or without ( Figure 6 , compound 19) the pendant 2-phenyl group were completely inactive. Similarly, removal of the 2-(4-chloro)phenyl ring resulted in complete abrogation of effect ( Figure 6, compound 21) . The in vitro efficacy of evaluated compounds showed a high correlation to in vivo effects in the zebrafish xenograft model (Figure 6 ).
In summary, these results show that modification of the b-hydroxypiperidine moiety or change of the quinoline scaffold of Vacquinol-1 lead to dramatic shifts in potency, whereas substitutions on the scaffold and pendant 2-phenyl group are tolerated. Modifications that are expected to only marginally affect physicochemical properties-e.g., pKa or logP-gave large variations in activity, supporting the hypothesis that the compounds exert their phenotypic response through binding to a specific protein target (or targets). However, as all compounds were evaluated and triaged in the primary GC viability assay, beyond binding affinity to putative pharmacological targets, pharmacokinetic properties such as membrane permeability are likely contributing factors of compound efficacy in cells.
In Vitro Preclinical Profiling of Vacquinol-1
In vitro physicochemical testing of Vacquinol-1 (i.e., solubility, pK a , and logP/D) indicates typical characteristics of a cationic amphiphilic drug (eg., high basic pKa, high logP/D), albeit an apparent high solubility in artificial cerebrospinal fluid (ACSF). ADME profiling confirmed that Vacquinol-1 exhibits high apparent membrane permeability (Papp) in Caco-2 cell monolayers. A slight efflux was detected, which was completely inhibited by the GF120918 (Elacridar), an inhibitor of P-glycoprotein (Hyafil et al., 1993) . Further, Vacquinol-1 was metabolically stable in human and mouse liver microsomes, as well as in freshly prepared human hepatocytes. Thus, Vacquinol-1 is predicted to be highly absorptive over biological membranes and resilient to metabolism, which indicates high bioavailability (Table S3 ).
Attenuation of Tumor Growth In Vivo and Prolonging
Survival by Vacquinol-1 Based on these results, Vacquinol-1 appeared as a promising candidate molecule for the treatment of glioblastoma. The zebrafish xenograft glioblastoma model was developed for quantitative analyses of tumor development and infiltration in the host brain ( Figures S7D and S7E) . Within 1 week after fluorescently labeled U3013MG cells were injected, GCs rapidly expanded and formed a tumor cell mass within the ventricle and started to infiltrate the brain (Figures 7A and 7B ). The developing tumors stained for human nuclear antigen ( Figure S7D ). Quantification of area, fluorescence level, and infiltration (distance from ventricle) revealed beneficial effects of Vacquinol-1 on all parameters (10 days, 15 mM in aquarium water; Figures 7C-7I ). The ability of Vacquinol-1 to attenuate tumor progression was next examined in a mouse model for human GBM. NOD/SCID mice received intracranial injections of U3013M GCs, and the resulting tumor was allowed to develop for 7 weeks. All mice presented with large and highly vascularized tumors infiltrating the host brain and often displayed massive areas of necrosis, overtly observed during dissection of the brains (n = 5, Figure 7J1 ). Histopathologic analysis revealed several features of GBM, including pseudopalisading necrosis, mitotic cells, and extensive microvascular proliferation ( Figures  7J1-7J3 and S7F ). Tumors were highly immunoreactive for human Nestin (hNestin) and human GFAP (hGFAP). Vacquinol-1 (15 mM, 0.5 ml/hr) or vehicle (DMSO) were administered intracranially into the site of original cell deposit 6 weeks after engraftment. Despite the advanced stage of cancer at the time of Vacquinol-1 administration, whole-brain morphology was (G) Live imaging of GCs (15 mM Vacquinol-1). Images collected at times of major phenotypic changes. (H) (H1 and H12) Live imaging with interference contrast optics of GCs (Vacquinol-1, 3.5 mM). Note increase in vacuole number and size (arrowhead points at a vacuole expanding in size). Scale bars, 50 mm (C), 5 mm (E), 20 mm (G), 20 mm (H1), and 10 mm (H2). Abbreviations: s, seconds; min, minutes; SEM, scanning electron microscopy. See also Figure S4 and Movies S1, S2, and S3. (legend continued on next page) markedly normalized after 1 week treatment ( Figures 7J1 and  7K ). Tumors were invariantly smaller, and the area of necrosis and hGFAP and hNestin immunoreactivity was significantly reduced ( Figures 7L-7O and S7G) . Only tumor cells in Vacquinol-1-treated mice displayed a massive LAMP1 staining ( Figures  7P and 7Q) . These results show that Vacquinol-1 activates similar cellular responses in vivo as in vitro, that activation of this pathway is selective for GBM as no staining was observed in the host brain, and that it has the capacity when administered into the brain to attenuate tumor growth.
Encouraged by these results, we investigated the bioavailability of Vacquinol-1 in vivo by oral (p.o.), intravenous (i.v.), and intraperitoneal administration. The i.v. plasma kinetics lacked a clear distribution phase, which indicates a rapid tissue distribution (apparent distribution kinetic phase visible in brain i.v.) after administration and a relatively large calculated volume of distribution, as predicted by in vitro ADME data. The pharmacokinetics of Vacquinol-1 showed a maximal plasma exposure of 3,279 ng/ml and good penetrance into the brain with exposure of 1,860 ng/ml following a single oral dose of 20 mg/kg (Figures S7H, S7J, and S7K). As predicted from the in vitro evaluation of metabolic stability, Vacquinol-1 was highly stable in vivo with very low systemic plasma clearance (t 1/2 = 52 hr in plasma) (Figure S7H ). Based on these results, the ability of oral Vacquinol-1 administration (20 mg/kg) once daily for 5 days to affect disease progression was examined by MRI measurements of tumor volume in the above-described xenograft GBM model. Treatment started at 6 weeks after engraftment of U3013M GCs, and animals were analyzed at week 8. During dissection, brains from vehicle treated mice displayed hemorrhage, areas of necrosis, and increased brain weight (n = 7), whereas brains from Vacquinol-1-treated mice (n = 13) showed a normal brain morphology and had a normalized brain weight ( Figures 7S and S7I ). Analysis by MRI revealed large tumors in all vehicle-treated mice with significantly smaller (four animals) or complete absence (nine animals) of detectable tumors in Vacquinol-1-receiving mice ( Figures 7R, 7T , and S7L). These results urged us to examine whether survival can be prolonged by Vacquinol-1. Mice receiving oral administration of Vacquinol-1 2 weeks after engraftment of U3013M GCs (20 mg/kg once daily for 5 days) displayed a temporary 10.8% ± 8.1% loss of body weight but regained weight to controls 1-2 weeks after end of treatment. Vacquinol-1 significantly enhanced survival as compared to vehicle-treated mice. Vehicle-treated animals (n = 8) showed a median survival of 31.5 days, whereas only two of the eight Vacquinol-1-treated mice died during the 80 days of the experiment ( Figure 7U , p = 0.0004 Mantel-Cox test). Hence, we conclude that oral administration of Vacquinol-1 substantially impairs disease progression and prolongs survival.
DISCUSSION
We have undertaken a functional screen of GCs based on the assumption that the accumulation of genetic alterations affecting intracellular signaling pathways underlying tumorigenesis also can result in gained cellular vulnerability not necessarily involved in the cancerous process. One biological process was identified in this screen that resulted in a robust loss of viability and increased display of cytotoxicity in GCs. The effect occurs independently of engaging apoptotic or autophagic pathways or overtly compromising mitochondria. Instead, cytotoxicity was found to be conferred by a mechanism involving induction of massive macropinocytosis, resulting in catastrophic vacuolization and death. This effect was found only in GCs, as mESCs, fibroblasts, mouse astrocytes, neurons, and several other types of cancer cells did not respond similarly to Vacquinol-1.
The biological process initiated by Vacquinol-1 involves massive membrane ruffling and blebbing within seconds after stimuli onset, cell rounding, followed by vacuole formation, which, in a time and concentration-dependent manner, increases in number and size and eventually leads to a disruption of cell membrane integrity and cell death. The molecular target of Vacquinol-1 and/or enrichment of downstream signaling pathways appear to confer a specificity of vacuolization to GBM cells. The massive buildup of vacuoles shows that any clearance of vacuoles by recycling or fusion with other endosomal compartments is insufficient. These characteristics are shared with macropinocytic vacuoles observed by forced expression of constitutively activated Ras (Bhanot et al., 2010; Overmeyer et al., 2008) . Because TMRE staining of mitochondria was not affected, indicating that membrane potential is unperturbed, we believe that the energy-consuming processes of massive membrane ruffling, retraction of blebs, and acidification of vacuoles contributes to the cellular depletion of ATP and is part of the high cytotoxicity of Vacquinol-1. Blebs are typically associated with macropinocytosis and are caused by a loss of the tight contact between the plasma membrane and the underlying layer of actin and myosin cortex, which holds the membrane under tension. Thus, when the plasma membrane separates from the cortex, the cytoplasmic pressure leads to formation of membrane blebs, which lacks the actin cytoskeleton (Charras and Paluch, 2008) . The retraction of blebs is associated with actin reassembly and reattachment of the membrane to the actin cortex. During the final stage of Vacquinol-1-induced cell toxicity, we often observed by live imaging an initial cytoplasmic membrane contraction followed by a very fast expansion of the membrane, resulting in lysis of the cytoplasmic membrane. This finding is consistent with actin reassembly followed by a complete dissolving actin cortex attachment and thereby release of the tension exerted by the hydrostatic pressure of the cytoplasmic membrane, leading to its fast expansion and lysis. This process is expected to be affected both by an increased membrane tension due to the diminishing content of cytoplasmic membrane caused by the vacuolization and by depletion of ATP that is required for actin reassembly.
Glioblastomas are highly aggressive and infiltrative and frequently recur after treatment. The main therapy involves radiation and chemotherapy with temozolomide (TMZ) (Stupp et al., 2005) that act by reducing cell viability causing apoptosis and senescence (Gü nther et al., 2003) . Precisely how recurrence occurs is unknown but may involve clonal expansion of cells with accumulated mutations, rendering cells refractive to current treatment strategies (Zhang et al., 2010) . Cellular heterogeneity of glioblastoma may also contribute to tumor recurrence, as the endogenous glioma cells with properties of cancer stem cells is a quiescent population (Alcantara Llaguno et al., 2009; Singh et al., 2004) . TMZ and radiotherapy act primarily on rapidly dividing cells and may fail in due course because they cannot kill the subpopulation of relatively quiescent tumor-initiating cells (Bao et al., 2006; Chen et al., 2012a) . The molecular action of Vacquinol-1 on macropinocytosis is expected to be independent of cell proliferation and therefore should target relatively quiescent stem-like tumor-initiating cells with similar efficiency as rapidly dividing cells. As it targets a new and independent pathway, Vacquinols are also expected to be efficient for drugresistant cancer. Although Vacquinols could be efficient as monotherapy, the rapid loss of ATP would be expected also to potentiate cytotoxicity in combination therapy approaches.
The in vitro preclinical profiling and in vivo pharmacokinetics of Vacquinol-1 indicate promising CNS drug properties such that it is highly stable in vitro/in vivo with low systemic clearance and high passive permeability and that it displays good penetrance into the brain. Mice were found to be highly tolerant to Vacquinol-1, as administration with 20 mg/kg p.o. for 5 days did not result in a sustained weight loss, showing that the potential buildup of high plasma concentrations at steady state does not compromise survival. These results suggest that an adequate concentration for cytotoxicity of glioblastoma without severe unwanted effects to transpire possibly can be achieved in vivo following administration.
Macropinocytosis is induced by the activation of tyrosine kinase receptors, integrins, or other cell-surface receptors, which causes a general elevation of actin polymerization at the cell surface, resulting in membrane ruffles that close at the distal margins to engulf extracellular fluid (Haigler et al., 1979; Mercer and Helenius, 2012; Swanson, 2008) . Thus, when ruffles curve into open, crater-like cups at the cell surface membrane, ruffle closure is followed by cup closure, separating the macropinosome from the plasma membrane. The massive cell ruffles observed after Vacquinol-1 addition, followed by cell membrane invaginations, could therefore be closely linked to the formation of macropinosomes.
The MAPKK, MKK4 encoded by MAP2K4, was found as a key signaling element for Vacquinol-1-induced macropinocytosis. MKK4 belongs to the stress/GPCR agonists/cytokine/growth factor-activated pathway, which previously is associated with inflammation, apoptosis, growth, and differentiation processes (Morrison, 2012 ), but we cannot find any previous knowledge on its participation in vacuolization. MAP2K4 loss of function is observed at 5% across a wide spectrum of cancers, including those of the breast, lung, pancreas, bile duct, prostate, and ovary, but its role appears complex, and both tumor suppressor and pro-oncogenic activities are consistent with its engagement in multiple cellular processes (Whitmarsh and Davis, 2007) .
The mechanism of MKK4 activation and its requirement for macropinocytosis and vacuolization are not fully understood but could be engaged downstream of Ras-activated Rac1. MAP2K4 has not been shown to be mutated in GBM, but nearly all tumors (88%) display alterations in receptor tyrosine kinase/ Ras signaling. Constitutively active Ras, if ectopically expressed, can drive macropinocytosis in a glioblastoma cell line (Kaul et al., 2007; Overmeyer et al., 2008) . It is possible that an elevated Ras signaling participates in MKK4 activation in glioblastoma and underlies the vulnerability of GCs to Vacquinol-1-induced vacuolization. However, GCs displayed a low constitutive uptake of LY in the absence of Vacquinol-1, indicating that endogenous Ras activity in these tumor cells is insufficient by itself for initiating high levels of macropinocytic activity. The critical role of MKK4 for macropinocytosis warrants studies to determine whether it is essential for induction of macropinocytosis in all its forms, including physiological processes, for instance, during uptake of bacteria, apoptotic bodies, necrotic cells, and viruses.
Vacquinol-1 (NSC13316) stems from a class of b-aminohydroxyquinolines originally developed for antimalarial application (Brown and Jacobs, 1946; Pinder and Burger, 1968; Rapport and Senear, 1946) . A close analog to Vacquinol-1, NSC23925, has recently been reported to reverse P-glycoprotein-mediated efflux of several cancer drugs in multidrug-resistant cancer cell lines (Duan et al., 2009 (Duan et al., , 2012 , although no direct cytotoxic effect of the compound itself was evident. In GCs, however, NSC23925 displayed an IC 50 of 7.59 mM (Figure 6 ), only slightly less potent than Vacquinol-1. Compounds from the same class were recently described also as inhibitors of bacterial biofilm formation (Leó n et al., 2013) and as inhibitors of SHIP1/2 in multiple myeloma cell lines (Fuhler et al., 2012) .
Vacquinol-induced cell death does not appear to confer an unspecific cytotoxicity, as other cell types show marginal or no loss of viability in the presence of Vacquinol-1 at comparitive concen- trations. Accumulation of phase-lucent vacuoles is consistently observed in all active members of the Vacquinol family of compounds (data not shown) at 10-to 100-fold lower concentrations than the corresponding IC 50 of GC viability. No vacuoles could be observed in alternative cell lines, at any concentration, regardless of the level of cytotoxicity observed in these cells. We believe that induction of this phenotype is a critical contributor to in vivo efficacy.
The structure-activity relationship (SAR) of Vacquinols reveals an exquisite dependence on the piperidin-2-ylmethanol moiety in the 4 position of the quinoline. Few modifications were tolerated in this region, although variability could be introduced in other positions of the quinoline and/or the pendant phenyl group in the 2 position while maintaining effect. In contrast to the reported stereochemical superiority of a single isomer of NSC23925 in reversing Pgp-mediated drug resistance in SKOV-3 cell lines (Duan et al., 2012) , three of the four possible isomers of Vacquinol-1 were roughly equipotent (data not shown). Thus, we did not pursue a stereospecific synthesis.
The long in vivo half-life of Vacquinol-1, in concert with its quinine-like lipophilic amine structure, suggested that the compound may be lysosomotropic in character, similar to the autophagy inhibitor chloroquine. Chloroquine has been described as toxic for glioblastoma cell lines through the induction of autophagic vacuole accumulation (Geng et al., 2010) , a sensitizer of radiation-induced cell death of GCs (Firat et al., 2012) and as an adjuvant of conventional therapies of GBM (Sotelo et al., (legend continued on next page) 2006). However, chloroquine showed no intrinsic activity on GCs in our hands ( Figure 6 ) and induced no vacuole accumulation. In addition, electron microscopy reveals that vacuoles induced by Vacquinol-1 are single-membrane bound, thus not autophagosomal in origin.
In addition to the long in vivo pharmacokinetic profile and oral bioavailability, Vacquinol-1 exhibits favorable overall preclinical characteristics. Although in vivo tolerance appears high and could be adequate for clinical utility, one possible obstacle for further clinical development of Vacquinol-1 is the effective therapeutic window in vitro, as unrelated toxicity appears at around 15 mM. The identification of compounds with higher selective activity toward GCs may improve this window.
By taking an unbiased strategy, we have identified a vulnerability to a macropinocytosis-associated catastrophic vacuolization as a selective feature of GBM and provide evidence for its targeted induction by a small molecule. We provide mechanistic and molecular insights for the cellular processes and signaling pathways involved and describe the structure-activity relationship of Vacquinol-1 for maintaining activity. Furthermore, our results provide evidence for an efficient in vivo induction of the same signaling pathway in animal models of GBM and show that tumor development can markedly be attenuated without apparent effects on host brain tissue. Thus, we have identified an acquired cellular property in GBM that can be readily targeted with small molecules displaying suitable properties for clinical development that rapidly and selectively depletes glioblastoma cells, attenuates disease progression, and prolongs survival in a GBM animal model.
EXPERIMENTAL PROCEDURES
GC Isolation and Screen GBM grade IV biopsies were obtained and cultured according to Pollard et al. (2009) . The NCI Diversity Set II small-molecule library was screened on GC lines U3013 and U3047 and was compared with mESCs and fibroblast cells to identify compounds affecting only GCs. The identified compounds were then exposed to a panel of other GC lines (U3013, U3047, U3024, U3031, U3037, U3086, U3054, and U3065), and the effect was documented.
Multiparametric Assays
Multiparametric assays of the 63 and 17 compounds were conducted in 384-well microtiter plates seeded with 10,000 cells. Cell viability, cytotoxicity, and apoptosis were measured using CellTiter-Glo Luminescent Cell Viability Assay, CytoTox-Glo Cytotoxicity Assay, and Caspase-Glo 9 Assay (Promega) according to the manufacturer's instructions. Mixed culture assay was performed with 1,000 labeled cells in hanging drop cultures. The dilution and recovery assay was performed by 2 day compound treatment followed by analysis after an additional 2 days without compound on GCs. Cell-cycle profiling was performed by propidium iodine flow cytometry and apoptosis by quantitative flow cytometry. Ratiometric calcium imaging and ADME analyses were performed according to previously published procedures. IC 50 was determined using Cell Viability assay.
Live Imaging and In Vivo Tests
Live imaging was performed on an Operetta High Content imaging system (PerkinElmer). Toxicity on embryos and cardiac toxicity was assessed in Zebrafish. For tumor development, zebrafish or NOD-SCID mice were injected with 3,000 or 100, 000 cells, respectively.
RNAi Screen
We used a DECIPHER lentiviral shRNA library consisting of Human Module 1, which includes a targeting of signaling pathways. In total 27,500 shRNAs targeting 5,043 genes were used. Viruses enriched in surviving cells after Vacquinol exposure (14 mM) were identified by deep sequencing.
Chemical Synthesis
Chemical syntheses were performed at CBCS, Karolinska Institutet, Stockholm, Sweden and SAI Life Sciences, Hyderabad, India. All final compounds were purified to R95% purity according to UV detection (305 ± 90 nm) and identity verified by mass spectrometry (MS) and NMR spectra before evaluated in biological assays. A full description of chemistry and associated analyses can be found in the Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one data file, three tables, and three movies and can be found with this article online at http://dx.doi. org/10.1016/j.cell.2014.02.021.
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